Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained

J. S. Wolinsky, G. Comi, M. Filippi, D. Ladkani, S. Kadosh, G. Shifroni

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

All but 6% of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European/Canadian MRI trial entered an open-label extension with quarterly clinical and MRI evaluations for another 9 months. There was a 54% reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6% reduction for those always on glatiramer acetate. Over the entire study the accumulated T2 disease burden was 34.2% less for those always on glatiramer acetate.

Original languageEnglish
Pages (from-to)1284-1286
Number of pages3
JournalNeurology
Volume59
Issue number8
Publication statusPublished - Oct 22 2002

Fingerprint

Placebos
Glatiramer Acetate

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Wolinsky, J. S., Comi, G., Filippi, M., Ladkani, D., Kadosh, S., & Shifroni, G. (2002). Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology, 59(8), 1284-1286.

Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. / Wolinsky, J. S.; Comi, G.; Filippi, M.; Ladkani, D.; Kadosh, S.; Shifroni, G.

In: Neurology, Vol. 59, No. 8, 22.10.2002, p. 1284-1286.

Research output: Contribution to journalArticle

Wolinsky, JS, Comi, G, Filippi, M, Ladkani, D, Kadosh, S & Shifroni, G 2002, 'Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained', Neurology, vol. 59, no. 8, pp. 1284-1286.
Wolinsky JS, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G. Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology. 2002 Oct 22;59(8):1284-1286.
Wolinsky, J. S. ; Comi, G. ; Filippi, M. ; Ladkani, D. ; Kadosh, S. ; Shifroni, G. / Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. In: Neurology. 2002 ; Vol. 59, No. 8. pp. 1284-1286.
@article{f06ae84ee4be42189e2cf1160cc2d3d0,
title = "Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained",
abstract = "All but 6{\%} of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European/Canadian MRI trial entered an open-label extension with quarterly clinical and MRI evaluations for another 9 months. There was a 54{\%} reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6{\%} reduction for those always on glatiramer acetate. Over the entire study the accumulated T2 disease burden was 34.2{\%} less for those always on glatiramer acetate.",
author = "Wolinsky, {J. S.} and G. Comi and M. Filippi and D. Ladkani and S. Kadosh and G. Shifroni",
year = "2002",
month = "10",
day = "22",
language = "English",
volume = "59",
pages = "1284--1286",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained

AU - Wolinsky, J. S.

AU - Comi, G.

AU - Filippi, M.

AU - Ladkani, D.

AU - Kadosh, S.

AU - Shifroni, G.

PY - 2002/10/22

Y1 - 2002/10/22

N2 - All but 6% of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European/Canadian MRI trial entered an open-label extension with quarterly clinical and MRI evaluations for another 9 months. There was a 54% reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6% reduction for those always on glatiramer acetate. Over the entire study the accumulated T2 disease burden was 34.2% less for those always on glatiramer acetate.

AB - All but 6% of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European/Canadian MRI trial entered an open-label extension with quarterly clinical and MRI evaluations for another 9 months. There was a 54% reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6% reduction for those always on glatiramer acetate. Over the entire study the accumulated T2 disease burden was 34.2% less for those always on glatiramer acetate.

UR - http://www.scopus.com/inward/record.url?scp=0037159225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037159225&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 1284

EP - 1286

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -